Changes in platelet count as a marker of myocardial iron uptake after administration of ferric carboxymaltose in patients with heart failure
Por:
Mollar, A, García-Conejo, C, Revuelta-López, E, Cardells, I, López, R, del Canto, I, de la Espriella, R, Lopez-Lereu, MP, Monmeneu, JV, Maceira, A, Lakhal-Littleton, S, Almenar, L, Cases, A, Peiró, M, Bayés-Genís, A and Núñez, J
Publicada:
12 ene 2026
Resumen:
Iron deficiency (ID) treated with ferric carboxymaltose (FCM) previously showed reduced platelet count; however, no studies have evaluated its biological significance in heart failure. In the current study, we aimed to: (a) assess the changes in platelet count at 7 and 30 days post-FCM, and (b) explore its association with non-invasive surrogates of myocardial iron uptake and left systolic function in patients with ID and heart failure with left ventricular ejection fraction < 50% (HFrEF and HFmrEF). This post-hoc analysis of a randomized, double-blind, FCM vs. placebo clinical trial (Myocardial-IRON Trail) involved 45 outpatients with HFrEF and HFmrEF and ID in which the platelet count value was available. Platelet count, cardiac magnetic resonance T1-mapping and 3D-global longitudinal strain (CMR-GLS) were assessed at baseline, 7, and 30 days. Linear regression models were used to evaluate the between-treatment differences and endpoints. The mean (SD) age was 71 +/- 8 years, and 32 (71%) were men. At 30 days, we found a significant reduction in platelet count in those treated with FCM (p-value = 0.027). In those treated with FCM, the greater 30-day decrease in platelets showed lower 30-day changes in T1-mapping (p = 0.024) and CMR-GLS (p = 0.028). After administration of FCM, we found a significant 30-day reduction in platelet count. The greater platelet count reduction was related to lower myocardial iron repletion and a smaller improvement in left ventricular systolic function.
Filiaciones:
Mollar, A:
Univ Valencia, Hosp Clin Univ Valencia, Dept Cardiol, INCLIVA, Avda Blasco Ibanez 17, Valencia 46010, Spain
CIBER Cardiovasc, Madrid, Spain
García-Conejo, C:
Univ Malaga, Dept Physiotherapy, Malaga, Spain
Biomed Res Inst Malaga & Platform Nanomed IBIMA Bi, Clinimetr Grp F 14, Malaga, Spain
:
CIBER Cardiovasc, Madrid, Spain
Hosp Universitari Germans Trias & Pujol, Serv Bioquim, Badalona, Spain
Fundacio Inst Invest Ciencies Salut Germans Trias, Campus Can Ruti, Barcelona, Spain
Cardells, I:
Hosp Manises, Dept Cardiol, Valencia, Spain
López, R:
Hosp Univ La Fe, Dept Cardiol, Valencia, Spain
del Canto, I:
Univ Valencia, Hosp Clin Univ Valencia, Dept Cardiol, INCLIVA, Avda Blasco Ibanez 17, Valencia 46010, Spain
CIBER Cardiovasc, Madrid, Spain
Univ Politecn Valencia, Ctr Biomat & Tissue Engn, Valencia, Spain
de la Espriella, R:
Univ Valencia, Hosp Clin Univ Valencia, Dept Cardiol, INCLIVA, Avda Blasco Ibanez 17, Valencia 46010, Spain
CIBER Cardiovasc, Madrid, Spain
Lopez-Lereu, MP:
Ascires Biomed Grp Valencia, Cardiovasc Imaging Unit, Valencia, Spain
Monmeneu, JV:
Ascires Biomed Grp Valencia, Cardiovasc Imaging Unit, Valencia, Spain
Maceira, A:
Ascires Biomed Grp Valencia, Cardiovasc Imaging Unit, Valencia, Spain
Lakhal-Littleton, S:
Univ Oxford, Dept Physiol Anat & Genet, Sherrington Bldg,Parks Rd, Oxford OX1 3PT, England
Almenar, L:
Hosp Univ La Fe, Dept Cardiol, Valencia, Spain
Cases, A:
Hosp Clin Barcelona, Barcelona, Spain
Peiró, M:
Univ Valencia, Dept Med, Valencia, Spain
:
CIBER Cardiovasc, Madrid, Spain
Univ Barcelona, Hosp Univ Germans Trias & Pujol, Inst Invest Biomeq, Cardiol Dept,Med Dept, Barcelona, Spain
Univ Barcelona, Hosp Univ Germans Trias & Pujol, Inst Invest Biomeq, Med Dept, Barcelona, Spain
Univ Autonoma Barcelona, Barcelona, Spain
Núñez, J:
Univ Valencia, Hosp Clin Univ Valencia, Dept Cardiol, INCLIVA, Avda Blasco Ibanez 17, Valencia 46010, Spain
CIBER Cardiovasc, Madrid, Spain
Univ Valencia, Dept Med, Valencia, Spain
Green Submitted, gold
|